BioMarin KSU | The Sentinel Newspaper / May 5, 2021
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
BioMarin News
KSU | The Sentinel Newspaper
BioMarin FiercePharma / May 4, 2021
How's this for a resume nugget? In each of Jean-Jacques Bienaime's 16 years as CEO at BioMarin, the California biotech has reported a revenue increase as it has worked to advance therapies against rare genetic diseases. As a result, Bienaime has been amply compensated.
BioMarin Yahoo Finance / May 4, 2021
In this article you are going to find out whether hedge funds think BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks [...]
Was The Smart Money Right About BioMarin (BMRN)?
Yahoo Finance
BioMarin Jumbo News / May 4, 2021
The most recent report entitled Global Myotonic Dystrophy Drug Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 by MarketQuest.biz sheds light on all the significant developments which are recently being adopted across the global market.
BioMarin Smarter Analyst / May 4, 2021
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biolinerx () and Verona Pharma () with bullish sentiments. Biolinerx (BLRX) In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Biolinerx, with a price target of $10.00.
Smarter Analyst
BioMarin Yahoo Finance / May 3, 2021
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN) as an investment opportunity by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model.
BioMarin GuruFocus.com / May 3, 2021
Investment company MADDEN SECURITIES Corp ( Current Portfolio) buys MP Materials Corp, Tesla Inc, The Trade Desk Inc, QuantumScape Corp, C3.ai Inc, sells Biomarin Pharmaceutical Inc, Corsair Gaming Inc, GoodRx Holdings Inc, Royal Gold Inc, Qualcomm Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, MADDEN SECURITIES Corp.
MADDEN SECURITIES Corp Buys MP
GuruFocus.com
BioMarin SoccerNurds / May 3, 2021
Zion market research has recently published a research study on Skeletal Dysplasia Market. The Global Skeletal Dysplasia Market Research Report Covers, Future Trends, Size, Share, Past, Present Data and Deep Analysis, And Forecast, 2021-2027 . To calculate the market size, the report considers revenue generated from the sales of products under the scope of the report.
BioMarin KSU | The Sentinel Newspaper / May 3, 2021
The Gaucher Disease Treatment Market is expected to grow at a CAGR of 7.71% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report.
BioMarin Smarter Analyst / May 3, 2021
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical () and Krystal Biotech () with bullish sentiments. Clearside Biomedical (CLSD) Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $6.00.
BioMarin SoccerNurds / May 1, 2021
The Hyperphenylalaninemia (HPA) Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
BioMarin SoccerNurds / May 1, 2021
The Therapeutic Enzymes Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
BioMarin Equities.com / May 1, 2021
Biomarin Pharmaceuticals (NASDAQ: BMRN) shares fell -2.82% to end trading Friday at $77.92 per share - a net change of $-2.26. Shares traded between $79.85 and $77.24 throughout the day. 1445936 shares of Biomarin Pharmaceuticals exchanged hands. Visit Biomarin Pharmaceuticals's profile for more information.
BioMarin SoccerNurds / May 1, 2021
The Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
BioMarin Yahoo Finance / Apr 30, 2021
Biotechnology company BioMarin Pharmaceutical (BMRN) posted 1Q results that beat analysts' estimates. Revenue decreased 3.2% year-on-year to $486 million but came in $39.65 million ahead of consensus forecasts. GAAP earnings per share came in at $0.09 versus analysts' estimates for a $0.10 loss.
BioMarin Reports Better-Than-Expected 1Q Results
Yahoo Finance
BioMarin Motley Fool / Apr 30, 2021
( Biomarin Pharmaceutical Inc NASDAQ:BMRN) Q1 2021 Earnings Call, 4:30 p.m. ET Prepared Remarks Questions and Answers Call Participants Operator Welcome to the BioMarin First Quarter 2021 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.
BioMarin InvestorsObserver / Apr 30, 2021
BioMarin Pharmaceutical Inc. ( BMRN) stock is down -14.52% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver's proprietary ranking system, gives BMRN stock a score of 16 out of a possible 100. That rank is mainly influenced by a short-term technical score of 4.
Is BioMarin Pharmaceutical Inc. (BMRN) Stock a Smart Investment Friday?
InvestorsObserver
BioMarin The Courier / Apr 30, 2021
Home / Request to Get the PDF Sample of the Report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=70067 Health The Report Studies Major Industry Key Players such as: /Dystrophin Market 2021 Industry Trends, Regional Demand, Growth Factors and Top Companies Asklepios BioPharmaceutical Inc, BioMarin Pharmaceutical IncAsk for Discount: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=70067 The Global Dystrophin Market Report recently published by Healthcare Intelligence Markets is a professional and in-depth study on the current state of the market industry.
The Courier
BioMarin KSU | The Sentinel Newspaper / Apr 30, 2021
Zion market research has recently published a research study on Batten Disease Treatment Market. The Global Batten Disease Treatment Market Research Report Covers, Future Trends, Size, Share, Past, Present Data and Deep Analysis, And Forecast, 2021-2027 . To calculate the market size, the report considers revenue generated from the sales of products under the scope of the report.
BioMarin Equities.com / Apr 30, 2021